Glenn Schulman
Investor Relations Kontakt bei IN8BIO, INC.
Aktive Positionen von Glenn Schulman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IN8BIO, INC. | Investor Relations Kontakt | 01.04.2024 | - |
Karriereverlauf von Glenn Schulman
Ehemalige bekannte Positionen von Glenn Schulman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PROKIDNEY CORP. | Investor Relations Kontakt | 31.08.2022 | - |
| X4 PHARMACEUTICALS, INC. | Investor Relations Kontakt | - | - |
| Public Communications Contact | - | - | |
| ACHILLION PHARMACEUTICALS, INC. | Public Communications Contact | - | - |
| AURINIA PHARMACEUTICALS INC. | Investor Relations Kontakt | - | 15.07.2022 |
| Public Communications Contact | - | - | |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Public Communications Contact | - | - |
Ausbildung von Glenn Schulman
| Philadelphia College of Pharmacy | Undergraduate Degree |
| Ernest Mario School of Pharmacy | Doctorate Degree |
| Yale University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 9 |
| Kanada | 2 |
Operativ
| Public Communications Contact | 4 |
| Investor Relations Contact | 4 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| PROKIDNEY CORP. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
- Börse
- Insiders
- Glenn Schulman
- Erfahrung
